Chemotherapy induced neutropenia is a very common side effect of cancer chemotherapy, it is treated on the basis of etiology, severity, and duration of the neutropenia. Growing prevalence of different forms of cancer and increasing research and development activities for novel therapeutics are primarily driving the growth of chemotherapy induced neutropenia market globally.

The report titled “Chemotherapy Induced Neutropenia Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall chemotherapy induced neutropenia market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on product, application and different geographical regions. Geographically, the global chemotherapy induced neutropenia market is studied for the following regional markets:   

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC
  • Rest of MEA

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global chemotherapy induced neutropenia market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global chemotherapy induced neutropenia market. This report concludes with company profiles section that highlights major information about the key players engaged in global chemotherapy induced neutropenia market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.    

Thus, the research study provides a holistic view of the global chemotherapy induced neutropenia market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.   

Based on the treatment, the global chemotherapy induced neutropenia market is segmented as follows:

• Antibiotic Therapy
• Colony-Stimulating Factor Therapy
• Granulocyte Transfusion
• Splenectomy Procedure

Chemotherapy induced neutropenia is a very common side effect of cancer chemotherapy, it is treated on the basis of etiology, severity, and duration of the neutropenia. Growing prevalence of different forms of cancer and increasing research and development activities for novel therapeutics are primarily driving the growth of chemotherapy induced neutropenia market globally. However, many of these medications are not available to patients in most countries, and even when registered they may not be reimbursed under public health insurance programs which may negatively impacting the growth of chemotherapy induced neutropenia market. There are different types of treatment available in market for chemotherapy induced neutropenia which are given on the basis of severity, it includes antibiotic therapy, colony stimulating factor therapy, granulocyte transfusion, splenectomy procedure and other therapy. It is observed that in the base year 2016, colony stimulating factor therapy is major revenue generating segment, due to its preferable use in treatment of chemotherapy induce neutropenia as they have ability to reduce the incidence and severity of neutropenia and febrile neutropenia while improving chemotherapy dose intensity. Regulatory guidelines recommend prophylactic G-CSF treatment for chemotherapy patients with an overall high risk (≥20%) is the prime factor that driving the growth of G-CSF market globally. Currently, Neupogen (filgrastim) and Neulasta (pegfilgrastim) held largest market share approved by the regulatory bodies for treatment of chemotherapy induced neutropenia.

For the purpose of this study, the global chemotherapy induced neutropenia market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

Chemotherapy induced neutropenia is the dose limiting toxicity of systemic cancer chemotherapy, it is the most serious hematologic toxicity and associated with the risk of life-threatening infections, as well as chemotherapy dose reductions. It is observed that currently, North America is major revenue generating segment due to factors such as increase in prevalence of different forms of cancer, upsurge funding by the government for life-threatening diseases such as cancer, high treatment awareness, higher investment in R&D by key players and research organizations are primarily driving the market growth in North America. On the other hand Asia Pacific is expected to show fastest growth during forecast period due to factors such as rising prevalence of different form of cancer, upsurge funding by the government and private organization for treatment, key manufacturers partnership with local manufacturers and rising treatment awareness would assist market growth in Asia Pacific.